FDA panel unanimously recommends approval for Reyataz
BY Advocate.com Editors
May 15 2003 12:00 AM ET
The Antiviral Drug Advisory Committee of the Food and Drug Administration on Tuesday unanimously recommended regulatory approval of the second-generation protease inhibitor Reyataz (atazanavir), developed by Bristol-Myers Squibb. Reyataz is recommended for approval for the treatment of HIV infection when taken as part of multidrug therapy. The protease inhibitor, the first that can be taken just once per day, has been shown in clinical trials to not raise blood lipid levels, a common side effect of currently available protease medications. A decision by the full FDA is expected early this summer.
- Texas Gay Man, 32, Dies in Custody After Being Denied Medication
- The True Meaning of the Word 'Cisgender'
- The Top 175 Essential Films of All Time for LGBT Viewers
- 10 Tips on Growing Older for LGBT People Under 40
- Alabama's Antigay Judge Roy Moore Slapped With New Ethics Charges
- Living Trans, From Iran to New York City